ACA
BPMC

Atlas Capital Advisors’s Blueprint Medicines BPMC Stock Holding History

Atlas Capital Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-170
Closed -$11.2K – 905
2022
Q3 		$11.2K Buy
+170
New +$10.9K ﹤0.01% 711
2022
Q2 		– Sell
-170
Closed -$10.9K – 979
2022
Q1 		$10.9K Buy
+170
New +$12.2K ﹤0.01% 695

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Atlas Capital Advisors's BPMC Position: Q4 2022 in Review

Atlas Capital Advisors sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 170 shares — an estimated $11.2K sold.

Atlas Capital Advisors first reported a position in BPMC in Q1 2022 and held it in 2 quarters. The position peaked at $11.2K in Q3 2022. 223 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

  • Atlas Capital Advisors reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 170 Blueprint Medicines shares in Q4 2022, an estimated $11.2K.
  • Atlas Capital Advisors first reported a position in Blueprint Medicines in Q1 2022 and held it in 2 quarters.
  • Atlas Capital Advisors's Blueprint Medicines position peaked at $11.2K in Q3 2022.
  • 223 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on Atlas Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.